Cargando…

Editorial: LRRK2—Fifteen Years From Cloning to the Clinic

Detalles Bibliográficos
Autores principales:	Rideout, Hardy, Greggio, Elisa, Kortholt, Arjan, Nichols, R. Jeremy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036085/ https://www.ncbi.nlm.nih.gov/pubmed/35478845 http://dx.doi.org/10.3389/fnins.2022.880914

Ejemplares similares

Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation
por: Gilsbach, Bernd K., et al.
Publicado: (2014)

LRRK2 Structure-Based Activation Mechanism and Pathogenesis
por: Zhang, Xiaojuan, et al.
Publicado: (2023)

LRRK2 Targeting Strategies as Potential Treatment of Parkinson’s Disease
por: Wojewska, Dominika Natalia, et al.
Publicado: (2021)

Allosteric inhibition of LRRK2, where are we now
por: Soliman, Ahmed, et al.
Publicado: (2020)

Activation Mechanism of LRRK2 and Its Cellular Functions in Parkinson's Disease
por: Rosenbusch, Katharina E., et al.
Publicado: (2016)

LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex
por: Cirnaru, Maria D., et al.
Publicado: (2014)

A Phosphosite Mutant Approach on LRRK2 Links Phosphorylation and Dephosphorylation to Protective and Deleterious Markers, Respectively
por: Marchand, Antoine, et al.
Publicado: (2022)

The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson’s Disease
por: Rideout, Hardy J., et al.
Publicado: (2020)

LRRK2 and neuroinflammation: partners in crime in Parkinson’s disease?
por: Russo, Isabella, et al.
Publicado: (2014)

The LRRK2 Variant E193K Prevents Mitochondrial Fission Upon MPP+ Treatment by Altering LRRK2 Binding to DRP1
por: Perez Carrion, Maria, et al.
Publicado: (2018)

Doubly Constrained C-terminal of Roc (COR) Domain-Derived Peptides Inhibit Leucine-Rich Repeat Kinase 2 (LRRK2) Dimerization
por: Pathak, Pragya, et al.
Publicado: (2023)

Characterization of Lipopolysaccharide Effects on LRRK2 Signaling in RAW Macrophages
por: Oun, Asmaa, et al.
Publicado: (2023)

Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation
por: Lobbestael, E., et al.
Publicado: (2016)

Insights into the Influence of Specific Splicing Events on the Structural Organization of LRRK2
por: Vlachakis, Dimitrios, et al.
Publicado: (2018)

LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson’s Disease, Where Do We Stand?
por: Taymans, Jean-Marc, et al.
Publicado: (2016)

Perspective on the current state of the LRRK2 field
por: Taymans, Jean-Marc, et al.
Publicado: (2023)

PAK6 Phosphorylates 14-3-3γ to Regulate Steady State Phosphorylation of LRRK2
por: Civiero, Laura, et al.
Publicado: (2017)

LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status
por: Reynolds, April, et al.
Publicado: (2014)

The WD40 Domain Is Required for LRRK2 Neurotoxicity
por: Jorgensen, Nathan D., et al.
Publicado: (2009)

A Critical LRRK at the Synapse? The Neurobiological Function and Pathophysiological Dysfunction of LRRK2
por: Kuhlmann, Naila, et al.
Publicado: (2020)

The tale of proteolysis targeting chimeras (PROTACs) for Leucine‐Rich Repeat Kinase 2 (LRRK2)
por: Konstantinidou, Markella, et al.
Publicado: (2020)

A Conserved Role for LRRK2 and Roco Proteins in the Regulation of Mitochondrial Activity
por: Rosenbusch, Katharina E., et al.
Publicado: (2021)

LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease
por: Kedariti, Maria, et al.
Publicado: (2022)

Levetiracetam treatment ameliorates LRRK2 pathological mutant phenotype
por: Rassu, Mauro, et al.
Publicado: (2019)

Conformational heterogeneity of the Roc domains in C. tepidum Roc–COR and implications for human LRRK2 Parkinson mutations
por: Rudi, Katharina, et al.
Publicado: (2015)

Autophagy and LRRK2 in the Aging Brain
por: Albanese, Federica, et al.
Publicado: (2019)

“LRRK2: Autophagy and Lysosomal Activity”
por: Madureira, Marta, et al.
Publicado: (2020)

Divergent Effects of G2019S and R1441C LRRK2 Mutations on LRRK2 and Rab10 Phosphorylations in Mouse Tissues
por: Iannotta, Lucia, et al.
Publicado: (2020)

Inhibition of the Exocyst Complex Attenuates the LRRK2 Pathological Effects
por: Ciampelli, Cristina, et al.
Publicado: (2023)

Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts
por: Petropoulou-Vathi, Lilian, et al.
Publicado: (2022)

Allosteric modulation of the GTPase activity of a bacterial LRRK2 homolog by conformation-specific Nanobodies
por: Leemans, Margaux, et al.
Publicado: (2020)

Activation of FADD-Dependent Neuronal Death Pathways as a Predictor of Pathogenicity for LRRK2 Mutations
por: Melachroinou, Katerina, et al.
Publicado: (2016)

LRRK2 modulates neuronal vesicles cycle through protein interactions
por: Piccoli, Giovanni, et al.
Publicado: (2015)

Pharmacodynamic Biomarkers for Emerging LRRK2 Therapeutics
por: Kelly, Kaela, et al.
Publicado: (2020)

LRRK2 Phosphorylation, More Than an Epiphenomenon
por: Marchand, Antoine, et al.
Publicado: (2020)

Modeling Parkinson’s disease in LRRK2 rodents
por: Domenicale, Chiara, et al.
Publicado: (2023)

Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice
por: Beccano-Kelly, Dayne A., et al.
Publicado: (2014)

LRRK2 dephosphorylation increases its ubiquitination
por: Zhao, Jing, et al.
Publicado: (2015)

Commentary on “Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice”
por: Popugaeva, Elena, et al.
Publicado: (2014)

Fifteen Years in Hell!
Publicado: (1857)

Cannot write session to /tmp/vufind_sessions/sess_cb1ed6b7p4inq3n8c883auldb5